Grade: pharmaceutical grade

Factory Location: JiangXi

Main Sales Markets: North America

Sample Provided: no

Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016.